THE WOODLANDS, Texas,
Jan. 7, 2015 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced
today that Lexicon management will present at the 33rd
Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 4:30 PM PST in San
Francisco. Lexicon management will provide an overview
of Lexicon's clinical development programs and milestones.
A webcast of the presentation will be available through
Lexicon's website at www.lexpharma.com. An archived version of the
presentation will be available at www.lexpharma.com until
February 14, 2015.
About Lexicon
Lexicon is a biopharmaceutical company focused on developing
breakthrough treatments for human disease. Lexicon has
clinical-stage drug programs for diabetes, carcinoid syndrome, and
other indications, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout
technology to identify more than 100 promising drug targets.
For additional information about Lexicon and its programs, please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon's ability to meet its capital
requirements, successfully conduct preclinical and clinical
development of its drug candidates, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2013, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-to-present-at-the-33rd-annual-jp-morgan-healthcare-conference-300017484.html
SOURCE Lexicon Pharmaceuticals, Inc.